Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03126435
Title EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors SynCore Biotechnology Co., Ltd.

pancreatic adenocarcinoma


EndoTAG-1 + Gemcitabine


Age Groups: adult | senior
Covered Countries USA | FRA

No variant requirements are available.